
    
      It will be evaluated whether 5-FU can be replaced by immunotherapy with cetuximab within a
      taxane/cisplatin-containing induction-chemotherapy scheme for advanced carcinoma of the head
      and neck. As 5-FU causes severe mucosal toxicities which are added to known toxicities of
      cisplatin, a combination-therapy with reduced toxicities and same efficacy would be a
      acceptable alternative to patients.
    
  